With a drive towards personalised medicine, Big Pharma is acting like mini-biotech firms in its approach to R&D, says Horizon Discovery who is launching a £25m ($42m) IPO.
MPI Research, inviCRO and 3D Imaging have partnered to build a Translational Imaging Center, providing molecular imaging, autoradiography, and animal modelling for pharmaceutical clients to investigate drug candidates.
Charles River Laboratories says it will shutter a Research Models and Services (RMS) facility in Michigan as softened demand for the sector offset a strong year for its preclinical service business.
The National Institutes of Health and 10 pharmaceutical companies have launched a partnership to transform the current model for identifying and validating promising biological targets for Type 2 diabetes, Alzheimer’s disease, lupus and rheumatoid arthritis.
Covance has sold its high-complexity genomics laboratory to LabCorp as part of what an analyst says is decisive action to shed underperforming assets in its Early Development business.
Sigma-Aldrich has teamed with Biopredic to produce genetically-modified human liver cell lines and assays it says can cut costs by reducing animal toxicology studies in drug discovery.
CRO Harlan Laboratories announced that it will open its first oncology research model breeding facility in India, which has already sparked anger in the animal rights community.
All the obvious cancer targets have been found according to Horizon Discovery, which last week agreed to help AstraZeneca find some new ones using isogenic pairs of oncology relevant cells.
The higher demand for preclinical toxicity testing reported by public CROs last year may also be being seen by private firms if recent investments are any indication.
Fewer animals were used to test the safety of life saving drugs in Europe in 2011 than in previous years according to the sixth edition of a research report by the European Commission last week.
The increasingly crowded Chinese preclinical model market gained a new entrant last month with US preclinical CRO Crown Bioscience partnering with Shanghai academics to set up a research centre.
Preclinical CRO Agilux has increased capacity at its research facility in Massachusetts, US, citing customer desire for faster in vivo studies as the driver for the investment.
Almac says it is in a unique position to offer Carbon-14 ADME radiolabeling for the growing antibody-drug conjugate (ADC) market and has already performed the service on a Pfizer candidate.
CRO Harlan Laboratories is partnering with BioXpert, a company specializing in laboratory animal science and services, to expand Harlan’s contract breeding services into Benelux, Germany. This was the second expansion in Europe over the last three months...
Third quarter growth in preclinical services was due to gain in market share and demand from Big Pharma, Charler River Laboratories (CRL) says as it reports solid Q3 earnings.
Covance produced solid Q3 results as expected by analysts though whether the CRO can fire both early and late stage development cylinders at once remains a question.
Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.
Discovery CRO Crown Biosciences has partnered with X-ray drug research specialist Xstrahl Life Sciences in a deal designed to make preclinical models that more accurately reflect clinical use of radiotherapy.
Enteris has secured its first partnership to develop metabolic peptides for Nordic Bioscience using an oral delivery platform it says offers unparalleled bioavailability.
Molecular Profiles has been chosen to develop topical and solid dose formulations of a preclinical psoriasis treatment as part of a multicompany conglomerate led by Telormedix.
Covance’s IT expenses are expected to taper off in 2014, which could contribute to driving wider margins for the CRO, Covance CFO Alison Cornell said Monday.
Bioreliance has launched an updated version of its mutagenicity service after conducting studies that confirmed its Big Blue Mouse assay still meets OECD standards.
Biofocus says it is literally bringing its scientists closer together to aid its drug discovery services with a new 60,000 square foot facility in Cambridge, UK.
Duke University will play contract research organisation (CRO) for clinical trials of a Parkinson’s disease treatment being developed by International Stem Cell Corp (ISCO).
Cutbacks are prompting more sponsors to outsource library design and screening during drug discovery according to UK-based software and consulting firm Cresset.
Covance has upgraded blood tube processing and kit production capabilities at its US central labs unit and says the efficiency drive is helping sponsors make better decisions.
CROs have an important role to play in reducing the number of animals used in drug development and – potentially – much to gain by doing so, according to the European Commission.
Over the next three years Pfizer will work with the Sanford Burnham Medical Research Institute to discover therapeutic targets to prevent and treat complications related to obesity and diabetes.
Agilent Technologies and SomaLogic will partner to expand the dissemination of Soma’s proteomic assay to at least five academic and contract research centers by the end of the year as demand for the tool has skyrocketed among biopharma companies.
CRO Covance is looking to help its biopharmaceutical and medical device clients manage their contract terms and associated payments better as some companies are losing almost 5% of US revenue from insufficient processes and contract management systems.
inVentiv Health and Oncobiologics are employing a unique risk-sharing partnership to bring a number of the biggest blockbuster biologics to market as biosimilars.
